September 18, 2009 — The US Food and Drug Administration (FDA) has approved a single-pill combination of the direct renin inhibitor aliskiren and the angiotensin receptor blocker valsartan ...

Valturna® is available in 2 dosages containing aliskiren/valsartan: 150 mg/160 mg and 300 mg/320 mg. The US approval was primarily based on an 8-week double-blind study in which 1797 patients ...

Several versions of valsartan and losartan also have been ... tablets have been recalled: • Irbesartan, 300 mg, 90 count, lot number 331B18009, expires February 2021 • Irbesartan HCTZ ...

In July, drug companies began recalling dozens of lots of the blood pressure and heart medications called valsartan, losartan and irbesartan after testing found the drugs had trace amounts of ...

Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg, had U.S. sales of approximately$1.6 billion for the 12 months ending June 30 ...

The statement reiterated the FDA estimate that “that if 8,000 people took the highest daily valsartan dose (320 mg) that contained NDMA, for four years (the time we think the affected products ...

Your doctor may start you on a dosage of 5 mg amlodipine/160 mg valsartan once daily. If your blood pressure is not controlled after 1–2 weeks, your doctor may increase your dosage. The maximum ...

This combination medication contains a calcium channel blocker and an angiotensin II receptor antagonist, prescribed for high blood pressure (hypertension).

Scientists from the FDA estimate that if 8,000 people took the highest valsartan dose (320 mg) from the recalled batches daily for four years, there may be one additional case of cancer over the ...

The target dose of 320 mg of the study drug was achieved at 4 weeks in 83.1% of the patients assigned to valsartan and in 85.2% of those assigned to placebo, and this dose was maintained in ...

Sarah Edwards is a seasoned legal writer with more than a decade of experience. Edwards has a deep understanding of advanced legal concepts and a knack for conveying complex topics in simple language.

The PIONEER-HF trial included 881 hemodynamically stabilized patients with acute decompensated HF with reduced EF who were randomly assigned to sacubitril 97 mg/valsartan 103 mg twice daily ...